↓ Skip to main content

Dove Medical Press

Article Metrics

Embed badge What is this page?

Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles

Overview of attention for article published in International Journal of Nanomedicine, September 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
18 Mendeley

What is this page?

Summary Twitter Dimensions citations
Title
Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles
Published in
International Journal of Nanomedicine, September 2017
DOI 10.2147/ijn.s141549
Pubmed ID
29026305
Authors

Mingfeng Shao, Wenfang Yang, Guangying Han

Abstract

Schisandrin B (Sch B) is clinically applied for the treatment of hepatitis and ischemic disease. However, its clinical efficacy is limited due to the poor solubility and low bioavailability. This study aimed to develop matrix metalloproteinase (MMP)-sensitive peptide-modified, polyethylene glycol (PEG)-modified (PEGylated) solid lipid nanoparticles (SLNs) for loading Sch B (MMP-Sch B SLNs), and to evaluate the therapeutic effect in the myocardial infarction model. PEG lipid and MMP-targeting peptide conjugate were synthesized. MMP-Sch B SLNs were prepared by solvent displacement technique. The physicochemical properties and pharmacokinetics of SLNs were investigated. In vivo effects on infarct size was evaluated in rats. The successful synthesis of lipid-peptide conjugate was confirmed. MMP-Sch B SLNs had a particle size of 130 nm, a zeta potential of 18.3 mV, and a sustained-release behavior. Higher heart drug concentration and longer blood circulation times were achieved by Sch B loaded SLNs than the drug solution according to the pharmacokinetic and biodistribution results. The best therapeutic efficacy was exhibited by MMP-Sch B SLNs by reducing the infarction size to the greatest extent. The modified SLNs may be a good choice for delivery of Sch B for the treatment of myocardial infarction.

View on publisher site

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 33%
Student > Bachelor 4 22%
Researcher 3 17%
Librarian 1 6%
Professor > Associate Professor 1 6%
Other 0 0%
Unknown 3 17%
Readers by discipline Count As %
Agricultural and Biological Sciences 3 17%
Medicine and Dentistry 3 17%
Pharmacology, Toxicology and Pharmaceutical Science 2 11%
Immunology and Microbiology 1 6%
Psychology 1 6%
Other 3 17%
Unknown 5 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 September 2017.
All research outputs
#9,455,604
of 11,834,771 outputs
Outputs from International Journal of Nanomedicine
#1,806
of 2,321 outputs
Outputs of similar age
#197,941
of 270,248 outputs
Outputs of similar age from International Journal of Nanomedicine
#49
of 65 outputs
Altmetric has tracked 11,834,771 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,321 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,248 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.

This page is hosted by Altmetric on behalf of Dove Medical Press.